Lupin acquires two diabetes brands from Germany's Boehringer Ingelheim for $28-M

Publicly listed, Mumbai-based pharma firm Lupin has acquired diabetes brands, namely Ondero (Linagliptin) and Ondero Met (Linagliptin + Metformin), from Germany-based Boehringer Ingelheim, including the trademark rights associated with these brands, for 26 million Euros (USD 28.29 M or INR 235 crore) in an all cash deal. Lupin has been marketing the two brands since 2015 in India in a co-marketing agreement with Boehringer Ingelheim India.